

Paracetamol (oral or rectal) for mild to moderate pain or fever

SESLHDPR/464

POLICY STATEMENT

The Registered Nurse (RN), Registered Midwife (RM) or Enrolled Nurse (EN) is authorised to instigate nurse/midwife-initiated medication without an authorised prescriber's order under the specific circumstances set out in the **INDICATIONS** section and provided there are no contraindications present.

An Enrolled Nurse (EN) may administer 'nurse-initiated medication' to adults and children greater than 16 years. The EN must confirm verbally with their supervising Registered Nurse prior to the administration that the medication is appropriate and safe for the patient. An EN with a notation because they do not hold board approved qualifications in the administration of medicines is NOT authorised to administer any medication⁵.

It is important for nursing and midwifery staff to remain aware that:

- Minor ailments may be symptoms of other more serious diseases or may be adverse reactions to medication already prescribed.
- Nurse-initiated medication may interact with the patient's prescribed medication.
- The maximum daily recommended dose of the medication must not be exceeded.1

The administering nurse/midwife must record the administration on an approved paper or electronic medication chart, clearly indicating that the medicine was nurse initiated.

If the patient continues to require the medication (i.e., more than two doses in 24 hours) then an authorized prescriber must be consulted and a regular or PRN order obtained.

A change in the patient's condition such as newly occurring or increasing severity of symptoms must be reported to the MO and investigated.

INDICATIONS

Analgesic and/or antipyretic in adults and children for mild to moderate pain and/or symptoms of fever when temperature is above 38.5 degrees C

Rectal paracetamol is an alternative to oral formulations for patients who are nil by mouth.

Rectal paracetamol should only be used when oral administration is not possible.

CONTRAINDICATIONS

- Hypersensitivity to paracetamol
- Conditions that make rectal administration inappropriate e.g., recent rectal or anal surgery, perianal or perineal abnormalities

Version: 5 Review date: August 2027 T15/37307 Page 1 of 6



PRECAUTIONS

- Do not use with any other paracetamol-containing products. The concomitant use with other products containing paracetamol may lead to an overdose.
- Impaired liver function may increase risk of further paracetamol related liver damage.
- Impaired kidney function may result in accumulation of paracetamol conjugates.
- Sodium restriction soluble products may contain large amounts of sodium
- Phenylketonuria soluble products may contain aspartame.

Version: 5 Review date: August 2027 T15/37307 Page 2 of 6



Paracetamol (oral or rectal) for mild to moderate pain or fever

SESLHDPR/464

- Dose adjustments may be required for patients with low body weight, patients with existing clinical conditions and any other factors affecting metabolism and excretion. Consult Medical Officer for advice.
- Safe to use in pregnancy (Australian category A) and breastfeeding.
- Additional precautions in children: fasting, vomiting, dehydration, toxic symptoms related to sepsis, or prior paracetamol intake (confirm with parent/carer).

HISTORY/ASSESSMENT

- Assess pain and/or fever symptoms (may include irritability, lethargy, and loss of appetite)
- Consult medication charts PRIOR to administration of paracetamol to ensure that a
 paracetamol-containing product is not already prescribed, and that paracetamolcontaining product has not been administered within the last 4 hours and is not due
 for administration in the next 4 hours. Ensure that this dose will not exceed the safe
 maximum daily dose from all sources for this patient.
- Check that patient is not receiving any drug/preparation which may interact with paracetamol.
- Consider referral to MO in those with precautions described above.

PROTOCOL/ADMINISTRATION GUIDELINES

Drug	Dose	Route		Frequency
Paracetamol	Children: 15 mg/kg/dose up to 1000 mg (maximum of 60 mg/kg/day or 4 g in 24 hours whenever is less) Adults: 500 mg to 1000 mg	Oral	rounded down to nearest suppository strength	Once only
	(maximum of 60 mg/kg/day or 4 g in 24 hours whenever is less)		125 mg, 250 mg, 500 mg	
	Consider reducing dose in those with risk factors for toxicity- see precautions. Caution with the strengths of different paediatric products, e.g., 50 mg/mL or mg/mL		•	

Version: 5 Review date: August 2027 T15/37307 Page 3 of 6



Caution with the strengths of suppository available and use of more than one product containing paracetamol, may lead to dosage errors and toxicity.

Use Personal Protective Equipment (PPE). Ensure outside wrap is removed from suppository prior to use and insert slowly beyond the anal sphincter.

Version: 5 Review date: August 2027 T15/37307 Page 4 of 6



Paracetamol (oral or rectal) for mild to moderate pain or fever

SESLHDPR/464

MONITORING - POTENTIAL ADVERSE EFFECTS/INTERACTIONS

Hypersensitivity reactions (e.g., rash, fixed drug eruption, toxic epidermal necrolysis and Stevens-Johnson syndrome), neutropenia, thrombocytopenia, pancytopenia, acute hepatitis may occur.

Interaction of warfarin and paracetamol may result in an increased risk of bleeding (prolonged regular use of paracetamol). Interaction of warfarin and paracetamol may result in increase in bleeding. Paracetamol absorption is decreased by gastric emptying drugs e.g. metoclopramide.

Rectal absorption can be erratic and delayed

DOCUMENTATION

A record of the administration must be made on the approved paper or electronic medication chart noting that the medication was nurse initiated.

A further record of the medication administered including indication, dose and effect must be included in the patient's health care record.

PRACTICE POINTS

- Onset of pain relief is approximately 30 minutes after oral administration
- Onset of pain relief is unpredictable after rectal administration
- Maximum single doses and maximum cumulative doses of paracetamol from all sources over 24 hours must not be exceeded.
- Minimal paracetamol dosing interval is 4 hours.
- Infants and children tolerate low-grade fever (e.g., less than 38–38.5°C) well, often respond to fluids and comfort and may not need paracetamol; there is no evidence that paracetamol prevents febrile seizures.
- Combining paracetamol and ibuprofen (or using an alternating regimen) to treat fever is not recommended.
- Lack of awareness of the strengths of different paediatric products, e.g., 50 mg/mL or 100 mg/mL, and use of more than one product containing paracetamol, may lead to dosage errors and toxicity; educate parents and carers appropriately.

REFERENCES/FURTHER READING

- 1. NSW Health Policy Directive Medication Handling PD2022 032
- 2. NSW Health Policy Directive High-Risk Medicines Management PD2020 045
- 3. <u>Australian Medicines Handbook.</u> Paracetamol. South Australia: Australian Medicines Handbook Pty Ltd, January 2023.
- 4. MIMs Online. Paracetamol (multiple products).
- 5. Medication: Administration by Enrolled Nurses SESLHDPD/160, 2018.
- 6. SESLHDMG/111: Medicine Guideline for the Safe Use of Paracetamol

Version: 5 Review date: August 2027 T15/37307 Page 5 of 6



Paracetamol (oral or rectal) for mild to moderate pain or fever

SESLHDPR/464

REVISION and APPROVAL HISTORY

Date	Version Number	Author and Approval
July 2015	DRAFT	Pharmacy Department, The Sutherland Hospital
September 2015	1	Aligned with PD2015_029
		Approved by SESLHD Drug & QUM Committee
May 2018	DRAFT 2	Reviewed by nursing and pharmacy staff. Minor
		wording updates made. References updated.
July 2018	2	Approved by SESLHD Quality Use of Medicines
		Committee
August 2021	DRAFT 3	Reviewed by nursing and pharmacy staff. Minor
		wording updates made. References updated.
September 2021	3	Approved by SESLHD Quality Use of Medicines
		Committee
June 2023	DRAFT 4	NSW Medicines Formulary reviewed. Concentration
		of paracetamol products updated. Reviewed by
		nursing and pharmacy staff.
September 2023	4	Approved by SESLHD Drug and Therapeutics
		Committee
August 2025	5	Oral and rectal NIMs merged. Approved by SESLHD
		Drug and Therapeutics Committee

Version: 5 Review date: August 2027 T15/37307 Page 6 of 6